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Introduction
Heparin inhibits thrombin generation by binding to anti-
thrombin III (AT-III), and heparin is widely used as an anti-
coagulant during percutaneous coronary interventions (PCI) 
and coronary artery bypass graft surgery (CABG) to prevent 
thromboembolic complications[1–3].  However, large variabil-
ity exits in individual heparin responsiveness[4, 5], and despite 
the theoretical possibility of increased periprocedural isch-
emic events associated with reduced heparin responsiveness 
(HRreduced), clinical evidence is either contradictory or limited.  
In patients undergoing PCIs, conflicting results exist with 
regard to the association between HRreduced and ischemic 
complications such as abrupt vessel closure during and after 
angioplasty[6–10].  In the surgical setting, only a single retro-
spective study has been performed to evaluate the relation-
ship between ischemic complications in patients undergoing 
on-pump CABG, which found a close correlation between 
HRreduced and fatal myocardial infarction (MI)[11].  
Surgical revascularization is also widely performed by off-
pump coronary artery bypass graft surgery (OPCAB) during 
which a similar degree of anticoagulation, as used during 
PCIs, is sufficient.  Unlike with PCIs, however, all patients 
presenting for OPCAB have previous exposure to heparin 
during coronary angiography, which is one of the well-estab-
lished risk factors of HRreduced[4, 5, 12].  Moreover, OPCAB still 
confers significant inflammatory responses and is associated 
with a postoperative procoagulant state relative to on-pump 
CABG[13, 14].  Concerning the possible relationship between 
HRreduced and an increased risk of ischemic events, there is 
still no clear recognition of patients with HRreduced or the clini-
cal significance of HRreduced in patients undergoing OPCAB at 
present.  
The aim of this study was to prospectively identify 
Heparin responsiveness during off-pump coronary 
artery bypass graft surgery: predictors and clinical 
implications 
Duk-hee CHUN1, #, Seong-wan BAIK2, #, So Yeon KIM3, Jae Kwang SHIM4, Jong Chan KIM3, Young Lan KWAK4, *
1Department of Anesthesiology and Pain Medicine, CHA Bundang Medical Center, CHA University, Sungnam, Korea; 2Department of 
Anesthesiology and Pain Medicine, Pusan National University College of Medicine, Busan, Korea; 3Department of Anesthesiology and 
Pain Medicine, Yonsei University College of Medicine, Seoul, Korea; 4Department of Anesthesiology and Pain Medicine, Anesthesia 
and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea 
Aim: To evaluate the clinical impact of reduced heparin responsiveness (HRreduced) on the incidence of myocardial infarction (MI) follow-
ing off-pump coronary artery bypass graft surgery (OPCAB), and to identify the predictors of HRreduced.  
Methods: A total of 199 patients scheduled for elective OPCAB were prospectively enrolled.  During anastomosis, 150 U/kg of heparin 
was injected to achieve an activated clotting time (ACT) of ≥300 s, and the heparin sensitivity index (HSI) was calculated.  HSIs below 
1.0 were considered reduced (HRreduced).  The relationships between the HSI and postoperative MI, cardiac enzyme levels and preopera-
tive risk factors of HRreduced were investigated.  
Results: There was no significant relationship between the HSI and cardiac enzyme levels after OPCAB.  The incidence of MI after 
OPCAB was not higher in HRreduced patients.  HRreduced occurred more frequently in patients with low plasma albumin concentrations and 
high platelet counts.
Conclusion: HRreduced was not associated with adverse ischemic outcomes during the perioperative period in OPCAB patients, which 
seemed to be attributable to a tight prospective protocol for obtaining a target ACT regardless of the presence of HRreduced.
    
Keywords: heparin responsiveness; off-pump coronary artery bypass graft surgery; risk factors; myocardial infarction
 
Acta Pharmacologica Sinica (2011) 32: 133–138; doi: 10.1038/aps.2010.180; published online 6 Dec 2010
Original Article
#  These authors contributed equally to this work.
* To whom correspondence should be addressed. 
E-mail ylkwak@yuhs.ac
Received 2010-06-09    Accepted 2010-09-15 
134
www.nature.com/aps
Chun DH et al
Acta Pharmacologica Sinica
npg
predictors of HRreduced and its clinical impact with regard to 
the incidences of MI and other major morbidity endpoints in 
the immediate postoperative period in patients undergoing 
OPCAB.  
Materials and methods
Patients 
This was a prospective study enrolling all consecutive patients 
scheduled for elective isolated multivessel OPCAB between 
April 2007 and March 2008 at a single university hospital. 
The approval of the institutional review board and patients 
consent were obtained.  Exclusion criteria were the presence 
of known preoperative coagulopathy, emergency surgery or 
preoperative use of an intra-aortic balloon pump.
Patients demographics; preoperative medications, includ-
ing anticoagulant therapy; and preoperative hematological 
and biochemical laboratory results, including hematocrit, total 
white cell count, percentage of neutrophils, platelet count, 
plasma protein and albumin concentrations, C-reactive protein 
(CRP), fibrinogen concentration, activated partial thrombo-
plastin time, and prothrombin time, as well as levels of myo-
cardial enzymes including creatinine kinase-MB (CK-MB) and 
troponin (Tn) T, were assessed.  Additionally, the preoperative 
AT-III concentration and activated clotting time (ACT) were 
assessed.  
All patients received standard anesthetic and surgical care 
according to institutional guidelines by physicians blinded to 
this study.
Measurement for ACT 
ACT was monitored with the Hemochron® Response Whole 
Blood Coagulation System (International Technidyne Corp 
(ITC), Edison, NJ, USA) using Hemochron HRFTCA510 celite 
ACT tubes.  
Heparin sensitivity index 
Baseline ACT was determined by blood sampling immedi-
ately after the insertion of the arterial line.  An initial dose 
of 150 U/kg of porcine heparin was injected into a central 
venous line just prior to Y-graft formation; the target ACT 
value was 300 s[15].  Ten minutes after the loading dose, the 
ACT was measured.  An ACT of 300 s or greater was con-
sidered adequate.  Then, a follow up ACT measurement was 
taken 30 min after the first ACT measurement.  If the ACT fell 
below the target value of 300 s, an additional dose of heparin 
was administered.  If the ACT was between 250 and 299 s, 
an additional 2000 U of heparin was administered, and if the 
ACT was between 200 and 249 s, then an additional 3000 U of 
heparin was injected.  Ten minutes after the injection of addi-
tional heparin, the ACT was remeasured.  Upon completion of 
anastomoses, the ACT was measured again, and the heparin 
activity was neutralized with protamine sulfate.  If the ACT 
was greater than 300 s, 50 mg of protamine sulfate was admin-
istered.  If the ACT was between 251 and 299 s or between 
200 and 250 s, 30 mg or 20 mg protamine sulfate was adminis-
tered, respectively.  Patients were considered to have HRreduced 
if the heparin sensitivity index [HSI, HSI=(post-heparin ACT 
– baseline ACT)/heparin loading dose (U/kg)] was below 1.0 
after the initial dose of 150 U/kg of heparin[16].  Patients with 
HSI≥1 were considered to have normal heparin responsive-
ness (HRnormal).
Variables assessed 
Intraoperative variables such as the total amount of heparin 
and protamine administered, the number and nature of grafts, 
the amount of blood loss and the amount transfused were 
recorded.  The amount of blood loss and blood transfused dur-
ing postoperative period, the coagulation profiles and myocar-
dial enzyme levels were recorded.
All of the patients were transferred to the intensive care unit 
(ICU) after surgery and treated with fentanyl-based intrave-
nous patient-controlled analgesia for 2–3 d for pain control, 
and anti-platelet therapy was started within 24 h unless con-
traindicated.
In the immediate postoperative period, the following vari-
ables were assessed.  The highest postoperative CK-MB and 
Tn-T levels were recorded during first seven postoperative 
days.  Clinical diagnostic criteria for MI were defined as the 
occurrence of an increase in cardiac enzyme levels five times 
above the upper normal limit; new Q waves of greater than 
0.04 mm or a reduction in R waves greater than 25% in at 
least 2 leads, or both; new ST elevation in at least 2 contiguous 
leads measuring more than 0.2 mV in leads V1–V3 or more 
than 0.1 mV in all other leads; or a new left bundle branch 
block[17].  Postoperative major morbidity endpoints were 
defined as permanent stroke, renal dysfunction, hemostatic 
re-exploration, deep sternal wound infection, and prolonged 
ventilation (>48 h)[18].  For clarification, renal dysfunction was 
defined as an acute postoperative renal insufficiency result-
ing in 1 or more of the following: (1) an increase in the serum 
creatinine level (Cr) to >2.0 mg/dL, (2) a ≥50% increase in Cr 
over the preoperative baseline value, or (3) a new requirement 
for dialysis.  The development of de novo atrial fibrillation was 
also assessed.  Patients were followed up for 6 months post-
operatively for cardiac morbidities/mortality and restenosis, 
which was defined as stenosis with a cross-sectional diam-
eter >50% at the site of bypass graft as assessed by computed 
tomography (CT) angiography.  Cardiac morbidities included 
Q-wave and non-Q-wave MI and the need for repeat revascu-
larization[19].  
Statistical analysis 
Statistical analyses were performed with SPSS 12.0 software 
(SPSS, Inc, Chicago, IL, USA).  Data were expressed as the 
mean±SD or as the number of patients (percentage).  Data 
were tested using the Pearson χ2 test, Mann-Whitney U-test 
or Student’s t test, as appropriate, to compare patients with 
HRreduced to patients with HRnormal.  Factors associated with 
HRreduced with a P value <0.05 in the univariate analysis were 
entered into a multivariate logistic regression analysis fol-
lowing a stepwise, forward model.  To evaluate the relation-
ship between the HSI and changes in cardiac enzyme levels 
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(highest postoperative cardiac enzyme level – preoperative 
cardiac enzyme level), linear regression analysis was per-
formed.  We determined that at least 148 patients would 
be required to detect a two-fold increase in the incidence of 
postoperative MI in patients with HRreduced[7] at an alpha level 
of 0.05 with 80% power, considering the 20% incidence of 
HRreduced[16, 20] in cardiac surgical patients and the 8% incidence 
of postoperative MI following OPCAB in our institute[21]. 
Results
A total of 199 patients were enrolled during this study period. 
Thirty-one (15.5%) of these 199 patients met the criteria for 
HRreduced (HSI range, 0.51 to 0.99).  In the HRnormal group, the 
HSI range was 1.00 to 4.04.  The patient characteristics were 
not different between the two groups.  Preoperative medica-
tions and the number of patients requiring continuous hepa-
rin use preoperatively were also similar between the groups 
(Table 1).  
The preoperative laboratory results indicated that patients 
with HRreduced were more likely to have significantly lower 
Hct, plasma total protein and plasma albumin concentrations; 
significantly higher neutrophil percentages, platelet counts, 
CRP and fibrinogen concentrations; and significantly short-
ened partial thromboplastin times compared to patients with 
HRnormal (Table 2).  In multivariate analysis, low plasma albu-
min concentrations (P=0.001, odds ratio 0.191, 95% confidence 
interval 0.073–0.498) and high platelet counts (P=0.033, odds 
ratio 1.006, 95% confidence interval 1.000–1.011) remained 
independent risk factors of HRreduced.  
During surgery, patients with HRreduced received significantly 
larger amounts of heparin and transfused red blood cells 
(Table 3).
There was no significant relationship between the HSI and 
changes in the CK-MB and Tn-T levels (P=0.804 and 0.904, 
respectively).  The HSI was also similar between the patients 
with and without postoperative myocardial infarction (1.5±0.5 
vs 1.5±0.4, P=0.939).  The incidence of perioperative MI within 
7 d and the incidence of other postoperative complications 
were not significantly different between the two groups 
(Table 4).  During the 6 month follow up period, none of the 
patients developed symptoms of ischemia except 1 patient in 
the HRnormal group who developed a symptomatic arrhythmia 
caused by restenosis of the venous graft to the right coronary 
artery and underwent PCI with a stent procedure.  CT angiog-
raphy was performed in 105 patients and 16 patients of the 
HRnormal and HRreduced groups, respectively.  Sixteen patients in 
the HRnormal group met the predefined criteria of restenosis, in 
contrast to none of the patients in the HRreduced group (Table 4).
Discussion
In this prospective study evaluating the risk factors for 
Table 1.  Patients’ characteristics. Data are expressed in numbers or 
mean±SD.
                                                HRnormal (n=168)       HRreduced (n=31)     P value  
 
Age (years) 64.0±8.5 65.5±9.6 0.361
Sex: male 120 (71%) 20 (65%) 0.439
Body surface area (m2) 1.72±0.17 1.68±0.19 0.199
MI within 1 week     6 (3.6%)   3 (9.7%) 0.149
MI within 1 month   12 (7.1%)   4 (12.9%) 0.224
Preoperative medications   
  β-blockers   97 (57.7%) 14 (45.2%) 0.136
  ACE inhibitors   57 (33.9%)   9 (29.0%) 0.379
  ARB   48 (28.6%)   8 (25.8%) 0.470
  Calcium channel blockers   72 (42.9%) 19 (61.3%) 0.058
  α and β blockers   44 (26.2%)   8 (25.8%) 0.580
  Sigmart 102 (60.7%) 19 (61.3%) 0.559
  Aspirin 138 (82.1%) 24 (77.4%) 0.779
  Clopidogrel 129 (76.8%) 25 (80.6%) 0.490
Intravenous heparin   50 (29.8%) 11 (35.5%) 0.525
LVEF (%)     56±13     53±14 0.192
LVEDD (mm)     50±5     52±7 0.064
Grade of MR ≥2     7 (4.2%)   2 (6.5%) 0.633
NYHA ≤2 152 (90.5%) 29 (93.5%) 0.744
NYHA ≥3   16 (9.5 %)   2 (6.5%) 0.744
Diseased vessel numbers   2.7±0.5   2.9±0.3 0.087
HRnormal, normal heparin responsiveness; HRreduced, reduced heparin 
responsiveness; MI within 1 week, myocardial infarction within 1 week 
prior to the surgery; MI within 1 month, myocardial infarction within 
1 month prior to the surgery; ACE, angiotensin converting enzyme; 
ARB, angiotensin receptor blocker; Intravenous heparin, preoperative 
intravenous heparin administration; LVEF, left ventricular ejection fraction; 
LVEDD, left ventricle end-diastolic diameter; MR, mitral regurgitation; 
NYHA, New York Heart Association Classification. 
Table 2.  Preoperative laboratory variables. Data are expressed in 
mean±SD.
                                                      HRnormal (n=168)   HRreduced (n=31)   P value  
 
Age (years)  64.0±8.5   65.5±9.6 0.361
Hematocrit (%)      38±5      35±5 0.001
Protein (g/L)     7.0±0.7     6.5±0.8 0.005
Albumin (g/dL)    4.3±0.5     4.0±0.4 0.001
WBC count (/μL) 7325±2006  7825±2570 0.312
Neutrophil (%)  58.4±9.4   63.0±12.2 0.017
Platelet count (×103/μL)   239±68    275±88 0.011
CRP (mg/dL)  6.27±11.7   13.6±26.7 0.014
Fibrinogen (mg/dL)   361±92    432±124 0.001
Prothrombin time (s)  11.0±2.6   11.0±1.3 0.880
Partial thromboplastin time (s)  39.0±16.3   32.2±9.3 0.003
CK-MB (ng/mL)    3.5±2.5     4.2±3.9 0.390
Troponin T (ng/mL)   0.19±1.35   0.71±2.24 0.256
AT-III (%)  94.3±15.5 101.7±16.0 0.073
Baseline ACT (s)   142±16    148±19 0.101
HRnormal, normal heparin responsiveness; HRreduced, reduced heparin 
responsiveness; WBC, white blood cell; CRP, C-reactive protein; CK-MB, 
creatine kinase-MB; AT-III, antithrombin-III; ACT, activated clotting time. 
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HRreduced and its association with MI and morbidity endpoints 
following OPCAB, low albumin concentrations and high 
platelet counts were identified as independent predictors of 
HRreduced.  However, the incidences of postoperative MI and 
morbidity endpoints including cardiac morbidities were not 
increased in patients with HRreduced.  
The use of heparin during procedures involving coronary 
arteries requires particular attention to decrease perioperative 
thrombogenesis without increasing the risk of bleeding.  Dur-
ing cardiopulmonary bypass (CPB), ACTs of less than 300 s 
caused coagulation in bypass circuits, and ACTs are recom-
mended to be longer than 400–480 s[1, 22].  Accordingly, a single 
retrospective review evaluating the impact of heparin respon-
siveness on ischemic complications within the first postop-
erative 48 h revealed that HRreduced was an important risk 
factor for fatal MI after on-pump CABG[11].  Additionally, in 
patients undergoing coronary balloon angioplasty, there was 
an inverse relationship between heparin responsiveness and 
the incidence of abrupt vessel collapse during and after angio-
plasty[7, 8, 23].  On the contrary, other studies involving patients 
undergoing stent insertion reported no correlation between 
heparin responsiveness and ischemic complica tions[9, 10], 
although there was a case of stent thrombosis associated with 
HRreduced[6].  
OPCAB constitutes an important axis as a surgical revas-
cularization technique of diseased coronary arteries, and 
by avoiding CPB, a reduced amount of heparin is required 
during surgery.  Based on previous studies, ACTs between 
250 and 300 s during OPCAB seem to be acceptable in many 
institutions[22, 24], and the majority of hospitals administered 
150 U/kg heparin at the beginning of graft anastomosis for a 
target ACT value of approximately 300 s[15], which is similar 
to that for PCI.  In view of the inflammation and coagula-
tion statuses, OPCAB stands in a unique position because it 
is still associated with significant inflammatory responses 
and the activation of the coagulation and fibrinolytic systems 
following mid-sternotomy and cardiac manipulation, which 
are more pronounced in OPCAB patients than in patients 
undergoing PCI[2, 25].  Moreover, it has been demonstrated that 
OPCAB is associated with a postoperative procoagulant state 
related to increases in prothrombin factor and von Willebrand 
factor and to transient platelet dysfunction compared to on-
pump CABG[13, 14].  In addition, unlike for PCI, all patients pre-
senting for OPCAB have previous exposure to heparin during 
coronary angiography, which is a well-known risk factor for 
HRreduced[4, 5, 12], and yet, evidence is lacking with regard to hep-
arin responsiveness and its clinical impact on OPCAB patients. 
Thus, we aimed to evaluate factors affecting HRreduced and the 
relationship between heparin responsiveness and postopera-
tive MI and morbidity endpoints.  
As our results indicate, patients with HSIs<1.0 composed 
16% of the study population, and low albumin concentra-
tions and high platelet counts were identified as independent 
predictors of HRreduced.  However, we did not observe any rela-
tionship between the HSI and changes in myocardial enzyme 
levels, and the HSI was also similar between patients with and 
without postoperative MI.  Plausible causes for these results 
are as follows.  Although previous studies found adverse 
ischemic outcomes in patients with HRreduced, these studies 
were either retrospective or did not prospectively manage the 
target ACT as in this study.  In the current trial, the ACT was 
Table 3.  Intraoperative and postoperative data. Data are expressed in 
numbers or mean±SD.
                                                     HRnormal (n=168)   HRreduced (n=31)    P value  
 
Intraoperative variables   
  Total heparin (units)                 10 753±2124     12 590±1832 <0.001
  Total protamine (mg)        42±11        43±15   0.836
  Bleeding (mL)      236±177      279±145   0.210
  pRBC (pack)       0.5±1.0     0.90±1.0   0.049
  FFP (pack)       0.5±1. 6       0.6±1.2   0.606
  p-conc (pack)       0.3±1.5       0.1±0.7   0.543
Postoperative variables   
  bleeding (mL)    1214±518    1291±453   0.440
  pRBC (pack)       0.6±1.3       0.6±1.0   0.962
  FFP (pack)       0.5±1.6       0.6±1.2   0.823
  p-conc (pack)       0.3±1.5       0.1±0.7   0.483
Graft numbers       3.3±0.7       3.5±0.6   0.051
  Arterial grafts       2.8±1.0       2.7±1.1   0.558
  Vein grafts     0.45±0.87     0.74±1.2   0.183
  Both arterial and vein grafts      42 (25%)     10 (32%)   0.398
Operation time (min)      249±50      266±36   0.067
Anesthesia time (min)      327±52      346±39   0.054
HRnormal, normal heparin responsiveness; HRreduced, reduced heparin 
responsiveness; pRBC, packed red blood cells; FFP, fresh frozen plasma; 
p-conc, platelet concentrates.
Table 4.  Postoperative outcome. Data are expressed in numbers or 
mean±SD.
                                             HRnormal (n=168)          HRreduced (n=31)     P value  
 
Highest CK-MB 13.4±17.1 11.2±8.7 0.511
Highest Tn-T 0.47±2.29 0.63±1.47 0.715
Postoperative MI 22 (13.1%) 2 (6.5%) 0.382
Stroke   2 (1.2%) 0 0.712
Renal failure 14 (10.1%) 2 (6.5%) 0.531
Reoperation   2 (1.2%) 0 0.712
Prolonged ventilation   1 (0.6%) 1 (3.2%) 0.288
A-fib development 40 (23.8%) 7 (22.6%) 0.544
Six months follow up   
cardiac morbidities   1 (0.6%) 0 1.000
restenosis 16/105 (15.2%) 0/16 (0%) 0.126
HRnormal, normal heparin responsiveness; HRreduced, reduced heparin 
responsiveness; CK-MB, creatine kinase-MB; Tn-T, troponin-T; MI, 
myocardial infarction; A-fib, atrial fibrillation; restenosis, confirmed by 
computed tomographic angiography. 
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closely monitored and maintained at >300 s prospectively 
by administering additive heparin if necessary during graft-
ing.  The ACT measured after the last heparin dose and before 
coronary anastomosis was above 300 s in all patients; this may 
be why HRreduced did not demonstrate any clinical relevance 
with respect to myocardial enzyme levels and MI during the 
perioperative period.  This is in accordance with the results 
of previous studies in the PCI setting in which ACT was pro-
spectively managed to be at least 225 s regardless of the pres-
ence of HRreduced[9, 10].  Considering that patients with HRreduced 
seemed to be in a preoperatively hypercoagulable state and 
that the minimum ACT during surgery was significantly lower 
in patients with HRreduced (297±44 s vs 253±23 s, P<0.001), it still 
might be important to acknowledge the risk in these patients 
and to perform additional and frequent ACT measurements to 
maintain an adequate ACT level and to titrate the heparin dos-
age during surgery.  Inflammatory markers such as CRP and 
the neutrophil percentages were not independent risk factors 
for HRreduced.  Perhaps the utilization of more distinct inflam-
matory markers such as interleukins could have resulted in a 
different outcome.  Unlike previous studies of cardiac surgery, 
in our study, the AT-III levels were not lower in patients with 
HRreduced, and only a few patients exhibited AT-III levels below 
60% (4 in the HRnormal and 1 in the HRreduced group).  Low AT-
III activity has been reported to contribute to HRreduced and 
hypercoagulability[26, 27] and could result in major thrombotic 
complications after PCI and on-pump CABG[28, 29].  Consider-
ing the significant decrease in AT-III activity during on-pump 
CABG[30], the different results compared to the previous study 
may also be partly attributable to the variable AT-III activity. 
Although, the HRreduced group received a significantly larger 
amount of heparin and transfused red blood cells during sur-
gery, it is difficult to establish a direct relationship between 
them because the HRreduced group initially had a lower hemat-
ocrit level.  
Heparin responsiveness potentially may influence not only 
the periprocedural morbidity but also the long term patency 
of grafted vessels.  Heparin inhibits the activation of the mito-
gen-activated protein kinase in vascular smooth muscle cells, 
and thus, the relative resistance to the antiproliferative action 
of heparin could be associated with long term graft patency[31]. 
In an in vitro study, heparin resistance in cultured vascular 
smooth muscle cells was a highly significant predictor of sub-
sequent vein graft stenosis[32].  Although there have been few 
studies evaluating whether a population clinically character-
ized by HRreduced during vascular procedures has concurrent 
hyperstenotic characteristics with an increased risk of graft 
stenosis, more careful follow-up is required in these patients. 
In this study, HRreduced was not associated with cardiac morbid-
ities or restenosis of graft vessels during a six month follow-up 
period after OPCAB.
The limitations of this study are as follows.  The anti-platelet 
therapy consisting of aspirin and clopidogrel was started 
empirically 24 h after surgery as appropriate, and the inter-
individual variability of clopidogrel responsiveness was not 
assessed, which might have affected the ischemic outcomes of 
the patients regardless of the HSI[33].
In conclusion, low plasma albumin concentrations and 
high platelet counts were identified as independent predic-
tors of HRreduced.  Despite a strong theoretical possibility and 
a close relationship between HRreduced and postoperative MI 
in on-pump CABG patients, HRreduced was not associated with 
adverse ischemic outcomes during the postoperative period 
after OPCAB.  A tight prospective protocol for obtaining a tar-
get ACT regardless of the presence of HRreduced seems to be of 
the highest importance while performing surgical revascular-
ization.
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